Difference between revisions of "Aprepitant (Emend)"
Jump to navigation
Jump to search
m (Text replacement - "[[Media:" to "[[File:") |
Warner-admin (talk | contribs) m (Text replacement - "please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [https://online.lexi.com/lco/action/login UpToDate Lexidrug], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information" to "please refer to your preferred pharmacopeias or the prescribing information") |
||
| (7 intermediate revisions by 3 users not shown) | |||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: Substance P/neurokinin 1 (NK1) receptor antagonist. | + | Class/mechanism: Substance P/neurokinin 1 (NK1) receptor antagonist. Aprepitant is able to cross the blood-brain barrier and blocks substance P activation of tachykinin family neurokinin 1 (NK1) receptors, which reduces the incidence of acute and delayed emesis.<ref name=insert>[http://www.merck.com/product/usa/pi_circulars/e/emend/emend_pi.pdf Aprepitant (Emend) package insert]</ref><ref>[[:File:Aprepitant.pdf | Aprepitant (Emend) package insert (locally hosted backup)]]</ref><ref>[http://www.emend.com/ Emend manufacturer's website]</ref> |
| − | <br>Route: PO | + | <br>Route: PO/IV |
<br>Extravasation: n/a | <br>Extravasation: n/a | ||
| − | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias | + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.<ref name="insert"></ref> |
==Patient drug information== | ==Patient drug information== | ||
*Brief patient counseling information can be found in the [http://www.merck.com/product/usa/pi_circulars/e/emend/emend_pi.pdf Aprepitant (Emend) package insert]<ref name="insert"></ref> | *Brief patient counseling information can be found in the [http://www.merck.com/product/usa/pi_circulars/e/emend/emend_pi.pdf Aprepitant (Emend) package insert]<ref name="insert"></ref> | ||
| − | *[http://www.uptodate.com/contents/aprepitant-patient-drug-information | + | *[http://www.uptodate.com/contents/aprepitant-patient-drug-information Aprepitant (Emend) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/aprepitant-patient-drug-information Aprepitant (Emend) patient drug information (UpToDate)]</ref> |
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | * | + | *2003-03-26: Approved for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy, including high-dose [[cisplatin]]. |
| − | *10 | + | *2005-10-28: Approved for prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy. |
| − | * | + | *2006-06-30: Approved for the prevention of postoperative nausea and vomiting. |
| − | + | ==History of changes in EMA indication== | |
| + | *2003-11-11: Initial authorization | ||
==Also known as== | ==Also known as== | ||
*'''Code name:''' MK-0869 | *'''Code name:''' MK-0869 | ||
| − | *'''Brand names:''' Cinvanti, Emend, Emend Trifold | + | *'''Brand names:''' Aponvie, Cinvanti, Emend, Emend Trifold |
==References== | ==References== | ||
| Line 24: | Line 25: | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
[[Category:Oral medications]] | [[Category:Oral medications]] | ||
| + | [[Category:Intravenous medications]] | ||
[[Category:Emesis prevention]] | [[Category:Emesis prevention]] | ||
[[Category:Neurokinin 1 (NK1) antagonists]] | [[Category:Neurokinin 1 (NK1) antagonists]] | ||
| + | [[Category:EMA approved in 2003]] | ||
[[Category:FDA approved in 2003]] | [[Category:FDA approved in 2003]] | ||
Latest revision as of 01:07, 29 June 2024
General information
Class/mechanism: Substance P/neurokinin 1 (NK1) receptor antagonist. Aprepitant is able to cross the blood-brain barrier and blocks substance P activation of tachykinin family neurokinin 1 (NK1) receptors, which reduces the incidence of acute and delayed emesis.[1][2][3]
Route: PO/IV
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.[1]
Patient drug information
- Brief patient counseling information can be found in the Aprepitant (Emend) package insert[1]
- Aprepitant (Emend) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 2003-03-26: Approved for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy, including high-dose cisplatin.
- 2005-10-28: Approved for prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy.
- 2006-06-30: Approved for the prevention of postoperative nausea and vomiting.
History of changes in EMA indication
- 2003-11-11: Initial authorization
Also known as
- Code name: MK-0869
- Brand names: Aponvie, Cinvanti, Emend, Emend Trifold